Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study
Cancer · 2023
DOI: 10.1002/cncr.34847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Caroline Hesko und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Vermont Children's Hospital, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms, Neuroblastoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Despite survival improvements, there is a paucity of data on neurocognitive outcomes in neuroblastoma survivors. This study addresses this literature gap.
Methods
Neurocognitive impairments in survivors were compared to sibling controls from the Childhood Cancer Survivor Study (CCSS) using the CCSS Neurocognitive Questionnaire. Impaired emotional regulation, organization, task efficiency, and memory defined as scores ≥90th percentile of sibling norms. Modified Poisson regression models evaluated associations with treatment exposures, era of diagnosis, and chronic conditions. Analyses were stratified by age at diagnosis (≤1 and >1 year) as proxy for lower versus higher risk disease.
Results
Survivors ( N = 837; median [range] age, 25 [17–58] years, age diagnosed, 1 [0–21] years) were compared to sibling controls ( N = 728; age, 32 [16–43] years). Survivors had higher risk of impaired task efficiency (≤1 year relative risk [RR], 1.48; 95% confidence interval [CI], 1.08–2.03; >1 year RR, 1.58; 95% CI, 1.22–2.06) and emotional regulation (≤1 year RR, 1.51; 95% CI, 1.07–2.12; >1 year RR, 1.44; 95% CI, 1.06–1.95). Impaired task efficiency associated with platinum exposure (≤1 year RR, 1.74; 95% CI, 1.01–2.97), hearing loss (≤1 year RR, 1.95; 95% CI, 1.26–3.00; >1 year RR, 1.56; 95% CI, 1.09–2.24), cardiovascular (≤1 year RR, 1.83; 95% CI, 1.15–2.89; >1 year RR, 1.74; 95% CI, 1.12–2.69), neurologic (≤1 year RR, 2.00; 95% CI, 1.32–3.03; >1 year RR, 2.29; 95% CI, 1.64–3.21), and respiratory (>1 year RR, 2.35; 95% CI, 1.60–3.45) conditions. Survivors ≤1 year; female sex (RR, 1.54; 95% CI, 1.02–2.33), cardiovascular (RR, 1.71; 95% CI, 1.08–2.70) and respiratory (RR, 1.99; 95% CI, 1.14–3.49) conditions associated impaired emotional regulation. Survivors were less likely to be employed full‐time ( p < .0001), graduate college ( p = .035), and live independently ( p < .0001).
Conclusions
Neuroblastoma survivors report neurocognitive impairment impacting adult milestones. Identified health conditions and treatment exposures can be targeted to improve outcomes. Plain Language Summary Survival rates continue to improve in patients with neuroblastoma. There is a lack of information regarding neurocognitive outcomes in neuroblastoma survivors; most studies examined survivors of leukemia or brain tumors. In this study, 837 adult survivors of childhood neuroblastoma were compared to siblings from the Childhood Cancer Survivorship Study. Survivors had a 50% higher risk of impairment with attention/processing speed (task efficiency) and emotional reactivity/frustration tolerance (emotional regulation). Survivors were less likely to reach adult milestones such as living independently. Survivors with chronic health conditions are at a higher risk of impairment. Early identification and aggressive management of chronic conditions may help mitigate the level of impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Vermont Children's Hospital, Burlington, Vermont, USA.
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
- National Cancer Institute, Washington, District of Columbia, USA.
- Duke University School of Medicine, Durham, North Carolina, USA.
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
ORCID-Profile: Caroline Hesko, Tara M Brinkman, Wendy M Leisenring, Kevin R Krull, Tara O Henderson
Förderung
- NCI NIH HHS
Zitieren
APA
Hesko, C., Liu, W., Srivastava, D. K., Brinkman, T. M., Diller, L., Gibson, T. M., Oeffinger, K. C., Leisenring, W. M., Howell, R., Armstrong, G. T., Krull, K. R., & Henderson, T. O. (2023). Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. https://doi.org/10.1002/cncr.34847
Vancouver
Hesko C, Liu W, Srivastava DK, Brinkman TM, Diller L, Gibson TM, et al. Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2023. doi:10.1002/cncr.34847
BibTeX
@article{Hesko2023,
author = {Hesko, Caroline and Liu, Wei and Srivastava, Deo K and Brinkman, Tara M and Diller, Lisa and Gibson, Todd M and Oeffinger, Kevin C and Leisenring, Wendy M and Howell, Rebecca and Armstrong, Gregory T and Krull, Kevin R and Henderson, Tara O},
title = {Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34847}
}
EUVIMED